Skip to main content
OpenTrials
Completed

NCT Number: NCT03727854

Effect of Premeal Protein-bar on Glycemic Control in Patients With Type 2 Diabetes

The aim of this study is to evaluate the effect of premeal protein-enriched bar in long-term glycemic control in patients with type 2 diabetes mellitus. Glucose levels in subjects who intake premeal protein-enriched bar with dietary modification will be compared to those in subjects who only do the dietary modification.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Seoul National University Hospital

Seoul, 110-744, South Korea

About this study

Forty subjects with type 2 diabetes will be recruited. Every subject will be randomized in two groups, which are premeal protein bar with dietary modification group and dietary modification only group. The study will be conducted for 12 weeks for each participants. All participants will receive diabetes diet education. Intervention group will consume protein-enriched bar before each meals (at least twice a day) and control group will follow diabetes diet education without other additional supplements. Primary outcome is change of HbA1c from baseline for 12 weeks, and secondary outcomes are changes of fasting blood glucose level, body weight, waist circumference, blood lipid level, HOMA-IR and HOMA-beta from baseline for 12 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 18.5~35 kg/m2
  • Type 2 diabetes patients
  • Fasting blood glucose ≥ 126 mg/dl or
  • HbA1c ≥ 6.5% or
  • Subjects who were previously diagnosed with type 2 diabetes and who have been treated with lifestyle modification only, oral anti-diabetic drugs or basal insulin.

Exclusion criteria

  • HbA1c < 6.5% or > 10%
  • Subjects using insulin other than basal insulin
  • Subjects who have newly started or have changed anti diabetic drugs within 3 months
  • Subjects who are allergic to grains, nuts, legumes and milk
  • Previous history of gastrointestinal surgery (except for hemorrhoid surgery, appendectomy surgery and hernia surgery)
  • Subjects with chronic unstable disease
  • Subjects with cognitive impairments who are not able to follow the study protocol
  • Females who are pregnant or doing breast feeding
  • Subjects with Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels of higher than 3 times of upper normal ranges
  • Subjects with hemoglobin level of less than 10.0 g/dL
  • Subjects with alcohol addiction or drug abuse

Treatment and study plan

Premeal protein enriched bar

Dietary Supplement

Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).

Dietary Modification

Behavioral

Subjects in this group will follow diabetes diet education.

Primary outcomes

  1. Change in HbA1c From Baseline

    Time frame: 0 week, 12 weeks

Secondary outcomes

  1. Change in Fasting Blood Glucose Level From Baseline

    Time frame: 0 week, 12 weeks

  2. Change in Body Weight From Baseline

    Time frame: 0 week, 12 weeks

  3. Change in Waist Circumference From Baseline

    Time frame: 0 week, 12 weeks

  4. Change in Blood Triglyceride Level From Baseline

    Time frame: 0 week, 12 weeks

  5. Change in Blood High-density Lipoprotein Level From Baseline

    Time frame: 0 week, 12 weeks

  6. Change in Blood Low-density Lipoprotein Level From Baseline

    Time frame: 0 week, 12 weeks

  7. Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) From Baseline

    Time frame: 0 week, 12 weeks

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is an index to estimate the insulin resistance of a subject. HOMA-IR is defined as ( glucose (mg/dl) X insulin (uIU/ml) ) / 405.

  8. Change in Homeostatic Model Assessment of β-cell Function (HOMA-beta) From Baseline

    Time frame: 0 week, 12 weeks

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is an index to estimate the insulin resistance of a subject. HOMA-IR is defined as ( glucose (mg/dl) X insulin (uIU/ml) ) / 405.

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Effect of Premeal Consumption of Protein-enriched, Dietary Fiber-fortified Cereal Bar on Long-term Glycemic Control in Patients With Type 2 Diabetes

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 1, 2018
Registry last updated
Apr 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.